| Neither APR elevated | APR levels discordant | Both APR elevated | P value |
---|---|---|---|---|
 | n = 2,520 | n = 1,058 | n = 650 |  |
Age (years) | 59.29 ± 13.22 | 62.21 ± 13.21 | 62.71 ± 13.34 | <0.0001 |
Duration of RA (years) | 11.01 ± 9.83 | 11.93 ± 10.68 | 10.91 ± 10.27 | 0.0406 |
One-year follow-up duration (days) | 362.63 ± 30.51 | 363.33 ± 31.06 | 363.46 ± 32.03 | 0.7410 |
mHAQ | 0.33 ± 0.40 | 0.45 ± 0.47 | 0.56 ± 0.54 | <0.0001 |
CDAI | 12.89 ± 10.15 | 15.18 ± 11.16 | 20.47 ± 14.68 | <0.0001 |
Tender joints | 3.73 ± 5.24 | 4.29 ± 5.40 | 6.30 ± 7.21 | <0.0001* |
Swollen joints | 4.04 ± 5.13 | 4.80 ± 5.49 | 6.64 ± 6.42 | <0.0001* |
Patient global assessment | 30.91 ± 23.82 | 36.35 ± 25.45 | 42.90 ± 27.56 | <0.0001 |
MD global assessment | 20.21 ± 16.61 | 24.67 ± 19.06 | 32.42 ± 22.50 | <0.0001 |
Prednisone use | 680 (26.98%) | 341 (32.23%) | 275 (42.31%) | <0.0001 |
Methotrexate use | 1,668 (66.19%) | 698 (65.97%) | 417 (64.15%) | 0.6166 |
Biologic use | 1,263 (50.12%) | 447 (42.25%) | 224 (34.46%) | <0.0001 |